(Vienna, 04 March 2021) Matthias Preusser, Head of the Division of Oncology of the Department of Medicine I at MedUni Vienna and Vienna General Hospital has been appointed Chair of the EORTC Brain Tumor Group, a working group of the European Organisation for Research and Treatment of Cancer.
The European Organisation for Research and Treatment of Cancer (EORTC) is a charitable organisation that studies cancer treatments and is headquartered in Belgium. It is one of the principal cancer research organisations in Europe. EORTC has a total of 17 international and interdisciplinary working groups, who jointly conduct treatment studies. EORTC is the only cancer research institution in Europe to have its treatment data accepted by the FDA in the USA for the purpose of drug licensing. The network has approximately 2,500 members from more than 300 different institutions throughout Europe.
The EORTC Brain Tumor Group is one of the main brain tumor study groups in the world. For example, its studies have defined several of the current therapeutic standards, e.g. for glioblastoma, oligodendroglioma and astrocytoma. Studies are currently underway to establish new therapeutic standards for other types of brain tumor.
The EORTC Brain Tumor Group comprises 265 international study centres in 35 countries and incorporates 511 international brain tumor specialists and multidisciplinary investigators. Under the leadership of Matthias Preusser, the mission statement will continue to be "Longer and better life for brain tumor patients".
Matthias Preusser is Professor of Internal Oncology at MedUni Vienna and Head of the Division of Oncology at the Department of Medicine I of MedUni Vienna and Vienna General Hospital.